Atezolizumab Doubles Survival of NSCLC Patients With Poor PS ...Middle East

Medscape - News
Patients with untreated NSCLC who could not withstand the rigors of platinum-based chemotherapy regimens had much better overall survival when treated with the immune checkpoint inhibitor atezolizumab. Medscape Medical News

Hence then, the article about atezolizumab doubles survival of nsclc patients with poor ps was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Atezolizumab Doubles Survival of NSCLC Patients With Poor PS )

Apple Storegoogle play

Last updated :

Also on site :